Literature DB >> 16165100

Use of bupropion in combination with serotonin reuptake inhibitors.

Sidney Zisook1, A John Rush, Barbara R Haight, Dawn C Clines, Carol B Rockett.   

Abstract

Incomplete symptom remission and sexual side effects are common problems for which bupropion often is added to treatment with selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for patients with major depressive disorder (MDD). This article reviews the literature on combining bupropion with SSRIs or SNRIs. We used MEDLINE to select studies that included patients diagnosed with MDD treated with any combination of bupropion and an SSRI or SNRI, either to enhance antidepressant response or to ameliorate antidepressant-associated sexual dysfunction. Bibliographies of located articles were searched for additional studies. Controlled and open-label studies support the effectiveness of bupropion in reversing antidepressant-associated sexual dysfunction, whereas open trials suggest that combination treatment with bupropion and an SSRI or SNRI is effective for the treatment of MDD in patients refractory to the SSRI, SNRI, or bupropion alone. The available data suggest that, although not an approved indication, the combination of bupropion and either an SSRI or an SNRI is generally well tolerated, can boost antidepressant response, and can reduce SSRI or SNRI-associated sexual side effects. Additional randomized controlled studies are needed to answer important questions, such as those regarding optimal dose and duration of treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165100     DOI: 10.1016/j.biopsych.2005.06.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  28 in total

1.  Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.

Authors:  Lin Pei; Shupeng Li; Min Wang; Mustansir Diwan; Hymie Anisman; Paul J Fletcher; José N Nobrega; Fang Liu
Journal:  Nat Med       Date:  2010-11-28       Impact factor: 53.440

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  Management strategies for SSRI-induced sexual dysfunction.

Authors:  Sakina J Rizvi; Sidney H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

4.  Tackling partial response to depression treatment.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

Review 6.  Anxious depression: clinical features and treatment.

Authors:  Sanjai Rao; Sidney Zisook
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

8.  Triple reuptake inhibitors: a premise and promise.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

9.  Triple reuptake inhibitors: the next generation of antidepressants.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

10.  Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.

Authors:  Ciara McCabe; Zevic Mishor; Philip J Cowen; Catherine J Harmer
Journal:  Biol Psychiatry       Date:  2009-12-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.